OREANDA-NEWS. According to the results of the year 2012 total sales of the top five best selling Rx drugs amounted to RUR 1,369.2 million, which corresponds to 37.2% of sales in the Rx drugs segment and 24.9%[1] of the Company’s total sales.

According to the results of the year 2012 the top five best selling Rx drugs are:

Geptor (Ademetionine; ATC[2] "Digestive tract and metabolism"); sales increased by 47% as compared to the same period of previous year; 12.5% of sales in the Rx drugs segment;

Irunine (Itraconazole; ATC "Antimicrobials for systematic use"); sales in the segment made 7%;

Cerepro (Choline Alfoscerate; ATC "Medications for the treatment of central nervous system deseases"); sales in the segment made 6.9%;

Vero-epoetin (Epoetin beta, ATC "Antineoplastic and immunomodulating agents"); sales in the segment made 5.7%;

Amigrenin (Sumatriptan, ATC "Medications for the treatment of central nervous system deseases"); sales in the segment made 5.2%;

OTC drugs

OTC drugs segment is characterized by the high degree of consolidation. It means that the top five best selling medicines make 98.7% of sales.

Xilen (Xylometazoline; ATC "Medications for the treatment of respiratory system"); sales increased by 7.6% as compared to the same period of previous year; sales in the OTC drugs segment made 57.4%;

Slabilen (Sodium picosulfate; ATC "Alimentary tract and metabolism"); sales increased by 1.2% as compared to the same period of previous year; sales in the OTC drugs segment made 24.6%;

Motilak (Domperidone; ATC "Alimentary tract and metabolism"); sales in the OTC drugs segment made 13.7%;

Vitasharm and Vitatress (ATC "Vitamins"); sales in the OTC drugs segment made 2.0%;

Ginecotex (Benzalkonium chloride; ATC "Medications for the treatment of urogenital organs"); sales in the OTC drugs segment made 0.9%.

Traditional drugs segment

According to the results of the year 2012 the top five best selling prescription medications are:

Vero-Dexamethasone (Dexamethasone; ATC "Hormonal drugs for systematic use"); sales in the traditional drugs segment made 39.2%;

Pyridoxine (ATC "Alimentary tract and metabolism"); sales in the segment made 27.1%;

Vero-Ciprofloxacin (Ciprofloxacin; ATC "Antimicrobials for systematic use"); sales in the segment made 11.1%;

Flukonazole (Fluconazole; ATC "Antimicrobials for systematic use"); sales in the segment made 10.1%;

Vero-Loperamide (Loperamide; ATC "Alimentary tract and metabolism"); sales in the segment made 7.8%.

Non-pharamaceutical products

According to the results of the year 2012 the top five best selling non-pharamaceutical products are:

Conventional antimicrobial adhesive bandages; 37.0% of sales in the segment;

Conventional reel adhesive bandages; 22.1% of sales in the segment;

Therapeutic patches - pepper plasters; 19.7% of sales in the segment;

Therapeutic patches - corn plasters; 18.8% of sales in the segment;

Nutritional therapy (Comida); 1.6% of sales in the segment.

NEW DRUGS PRODUCTION AND SALES

During 2012 Veropharm launched production and sales of the following new drugs and cosmetic products:

Poludan (Polyadenilic acid + Polyuridilic acid; ATC "Medications for the sense organs treatment"); new dosage – nasal drops 50 IU[3]/ml 5 ml №1;

Aprotex (Aprotinin, ATC "Medications affecting hematogenesis and blood"); new dosages - 10000 KIU[4]/ml 10 ml №1, 10000 KIU/ml 50 ml № 1 and 10000 KIU/ml 10 ml № 25;

Bergolak (Cabergoline; ATC "Medications for the urinogenital organs treatment"); new dosage – tabl. 0.5 mg №2;

Mielastra (Filgrastim; ATC "Antineoplastic and immunomodulating agents"); new dosages – 30 mln IU/ml 1.6 ml №1 and 30 mln IU/ml 1 ml №5;

Vero-Netilmicin (Netilmicin; ATC "Antimicrobials for systematic use"); new dosage – solution for injection 25mg/ml 2 ml №1;

Tautax (Docetaxel; ATC "Antineoplastic and immunomodulating agents"); new dosage – 20 mg/ml 2 ml №1;

Cerepro (Choline alfoscerate; ATC "Medications for the treatment of central nervous system deseases"); new dosage – 250 mg/ml 4 ml №5;

Rubida (Idarubicin, "Antineoplastic and immunomodulating agents"); new dosage – 1 mg/ml 10 ml №1;

Torin (Sertraline; ATC "Medications for the treatment of central nervous system deseases"); new dosage – tabl. 0.05g №28.

Parclitaxel-LENS (Parclitaxel; ATC "Antineoplastic and immunomodulating agents"); new dosage – 6 mg/ml 46 ml №1;

Verotecan (Topotecan, ATC "Antineoplastic and immunomodulating agents"); new dosage 1 mg №1;

Veromistin Silver (Benzyldimethyl-myristoikamino-propylammonium monohydrate, ATC “Medications for dermatopathy treatment”); new form - napkins for intimate hygiene;

Veromistin Daily (Benzyldimethyl-myristoikamino-propylammonium monohydrate, ATC “Medications for dermatopathy treatment”); new form – cleaning wet towels;

NEW DRUGS REGISTRATION

In the year 2012 Veropharm received registration for the following drugs:

Topotecan (Topotecan, ATC "Antineoplastic and immunomodulating agents"); new dosage - liophilizate for infusion solution 1 mg;

Veromistin Silver (Benzyldimethyl-myristoikamino-propylammonium monohydrate, ATC “Medications for dermatopathy treatment”); new form - napkins for intimate hygiene;

Veromistin Daily (Benzyldimethyl-myristoikamino-propylammonium monohydrate, ATC “Medications for dermatopathy treatment”); new form – cleaning wet towels;

Anfibra (Enoxaparin sodium; ATC "Medications affecting hematogenesis and blood");

Bereta (Rabeprazole; ATC "Digestive tract and metabolism")

Additionally, 22 more drugs are currently at different stages of the registration process.

[1] % - percent of finished goods sales

[2] ATC – anatomico-therapeutico-chemical group

[3] IU – international units

[4] KIU – kallikrein-inactivated unit